Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial

Autor: Mell, Loren K a, *, Torres-Saavedra, Pedro A b, Wong, Stuart J c, Kish, Julie A d, Chang, Steven S e, Jordan, Richard C f, Liu, Tian g, Truong, Minh Tam h, Winquist, Eric W i, Takiar, Vinita j, Wise-Draper, Trisha k, Robbins, Jared R l, Rodriguez, Cristina P m, Awan, Musaddiq J n, Beadle, Beth M o, Henson, Christina p, Narayan, Samir q, Spencer, Sharon A r, Powell, Steven s, Dunlap, Neal t, Sacco, Assuntina G u, Hu, Kenneth Shung v, Park, Henry S w, Bauman, Julie E x, Harris, Jonathan y, Yom, Sue S z, Le, Quynh-Thu o
Zdroj: In The Lancet Oncology December 2024 25(12):1576-1588
Databáze: ScienceDirect